Sean Caenepeel

3.4k total citations
22 papers, 1.3k citations indexed

About

Sean Caenepeel is a scholar working on Molecular Biology, Oncology and Hepatology. According to data from OpenAlex, Sean Caenepeel has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 10 papers in Oncology and 4 papers in Hepatology. Recurrent topics in Sean Caenepeel's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer-related Molecular Pathways (6 papers) and Liver physiology and pathology (4 papers). Sean Caenepeel is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Cancer-related Molecular Pathways (6 papers) and Liver physiology and pathology (4 papers). Sean Caenepeel collaborates with scholars based in United States, Australia and Netherlands. Sean Caenepeel's co-authors include Paul E. Hughes, Lawren C. Wu, Anne Y. Saiki, Jonathan D. Oliner, Gerard Manning, Sucha Sudarsanam, Tony Hunter, Michael Fill, Josefina Ramos‐Franco and Gregory A. Mignery and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Clinical Cancer Research.

In The Last Decade

Sean Caenepeel

22 papers receiving 1.2k citations

Peers

Sean Caenepeel
Michael Zinda United States
Shi-Yong Sun United States
Katti Jessen United States
Rumey C. Ishizawar United States
Richard Woessner United States
Nathan G. Dolloff United States
Yoko Ueno Japan
Steven A. Enkemann United States
Susan E. Morgan-Lappe United States
Suhu Liu United States
Michael Zinda United States
Sean Caenepeel
Citations per year, relative to Sean Caenepeel Sean Caenepeel (= 1×) peers Michael Zinda

Countries citing papers authored by Sean Caenepeel

Since Specialization
Citations

This map shows the geographic impact of Sean Caenepeel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sean Caenepeel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sean Caenepeel more than expected).

Fields of papers citing papers by Sean Caenepeel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sean Caenepeel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sean Caenepeel. The network helps show where Sean Caenepeel may publish in the future.

Co-authorship network of co-authors of Sean Caenepeel

This figure shows the co-authorship network connecting the top 25 collaborators of Sean Caenepeel. A scholar is included among the top collaborators of Sean Caenepeel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sean Caenepeel. Sean Caenepeel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wei, Andrew H., Andrew W. Roberts, Andrew Spencer, et al.. (2020). Targeting MCL-1 in hematologic malignancies: Rationale and progress. Blood Reviews. 44. 100672–100672. 152 indexed citations
2.
3.
Elbanna, May, Ashley Orillion, Nur P. Damayanti, et al.. (2019). Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Molecular Cancer Therapeutics. 19(1). 147–156. 10 indexed citations
4.
Navis, Anna C., Tessa J.J. de Bitter, Houshang Amiri, et al.. (2017). Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity. Molecular Cancer Research. 15(11). 1587–1597. 6 indexed citations
5.
Caenepeel, Sean, Keegan S. Cooke, Guo N. Huang, et al.. (2017). MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor. Oncotarget. 8(11). 17795–17809. 33 indexed citations
6.
Du, Zhiqiang, Sean Caenepeel, Yuqing Shen, et al.. (2016). Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 15(6). 1227–1237. 18 indexed citations
7.
Hughes, Paul E., Karen Rex, Sean Caenepeel, et al.. (2016). In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models. Molecular Cancer Therapeutics. 15(7). 1568–1579. 44 indexed citations
8.
Oliner, Jonathan D., Anne Y. Saiki, & Sean Caenepeel. (2016). The Role of MDM2 Amplification and Overexpression in Tumorigenesis. Cold Spring Harbor Perspectives in Medicine. 6(6). a026336–a026336. 177 indexed citations
9.
Hughes, Paul E., Sean Caenepeel, & Lawren C. Wu. (2016). Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer. Trends in Immunology. 37(7). 462–476. 211 indexed citations
10.
Stec, Markian M., Kristin L. Andrews, Yunxin Bo, et al.. (2015). The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitors. Bioorganic & Medicinal Chemistry Letters. 25(19). 4136–4142. 18 indexed citations
11.
Saiki, Anne Y., Sean Caenepeel, Elissa J. Cosgrove, et al.. (2015). Identifying the determinants of response to MDM2 inhibition. Oncotarget. 6(10). 7701–7712. 32 indexed citations
12.
Hughes, Paul E., Yajing Yang, Karen Rex, et al.. (2014). Abstract 728: AMG 337, a novel, potent and selective MET kinase inhibitor, has robust growth inhibitory activity in MET-dependent cancer models. Cancer Research. 74(19_Supplement). 728–728. 6 indexed citations
13.
Wurz, Ryan P., Longbin Liu, Kevin Yang, et al.. (2012). Synthesis and structure–activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold. Bioorganic & Medicinal Chemistry Letters. 22(17). 5714–5720. 23 indexed citations
14.
Zhang, Nancy R., Sean Caenepeel, Ling Wang, et al.. (2012). Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models. Cancer Research. 72(8_Supplement). 2797–2797. 1 indexed citations
15.
Stec, Markian M., Kristin L. Andrews, Shon K. Booker, et al.. (2011). Structure–Activity Relationships of Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Investigations of Various 6,5-Heterocycles to Improve Metabolic Stability. Journal of Medicinal Chemistry. 54(14). 5174–5184. 34 indexed citations
16.
Caenepeel, Sean, Lisa Renshaw-Gegg, Tammy L. Bush, et al.. (2010). Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. Journal of Experimental & Clinical Cancer Research. 29(1). 96–96. 15 indexed citations
17.
Coxon, Angela, Tammy L. Bush, Douglas C. Saffran, et al.. (2008). Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors. Clinical Cancer Research. 15(1). 110–118. 32 indexed citations
18.
Caenepeel, Sean, et al.. (2004). The mouse kinome: Discovery and comparative genomics of all mouse protein kinases. Proceedings of the National Academy of Sciences. 101(32). 11707–11712. 235 indexed citations
19.
Ramos‐Franco, Josefina, Dan J. Bare, Sean Caenepeel, et al.. (2000). Single-Channel Function of Recombinant Type 2 Inositol 1,4,5-Trisphosphate Receptor. Biophysical Journal. 79(3). 1388–1399. 75 indexed citations
20.
Ramos‐Franco, Josefina, Sean Caenepeel, Michael Fill, & Gregory A. Mignery. (1998). Single Channel Function of Recombinant Type-1 Inositol 1,4,5-Trisphosphate Receptor Ligand Binding Domain Splice Variants. Biophysical Journal. 75(6). 2783–2793. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael Zinda Breakdown of academic impact, for papers by Shi-Yong Sun Breakdown of academic impact, for papers by Katti Jessen Breakdown of academic impact, for papers by Rumey C. Ishizawar Breakdown of academic impact, for papers by Richard Woessner Breakdown of academic impact, for papers by Nathan G. Dolloff Breakdown of academic impact, for papers by Yoko Ueno Breakdown of academic impact, for papers by Steven A. Enkemann Breakdown of academic impact, for papers by Susan E. Morgan-Lappe Breakdown of academic impact, for papers by Suhu Liu
Rankless by CCL
2026